Claudia Zylberberg
Chief Executive Officer at Akron Biotechnology
Meet Claudia Zylberberg
Zylberberg is concerned about the lack of closed or automated systems in cell and gene therapy. “The closing of systems will provide opportunities to manufacture in different environments, such as hospitals, and will enhance the capability to scale-out many of these autologous therapies. Right now, you would need a CMO to manufacture them, but a closed system would allow you to manufacture anywhere. The logistics, globally, of these therapies is also one of the biggest pieces of the puzzle.” Akron has responded to the COVID-19 epidemic by offering its biomolecules, such as interferons and other novel formulations, to be further investigated. “These will hopefully be used to create solutions for early stages of infection and advance initiatives that we’ve proposed both independently and in collaboration with others.”